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II. ABSTRACT 
Candida glabrata is an emerging opportunistic pathogen that is known to develop 
resistance to azole drugs due to increased drug efflux. Resistance is mediated by a range 
of gain-of-function (GOF) mutations in CgPDR1, which are also known to enhance 
virulence. Recent data suggests that increased adherence to epithelial cells is partially 
responsible for the gained virulence, however it remains unclear which genes are 
implicated. In this study we used Real-Time quantitative PCR to analyze the influence 
of CgPDR1 GOF mutations on the expression of several cell wall proteins that are 
either known or predicted to play a role in the adhesion of yeast to host epithelial cells. 
CgPDR1 GOF mutations lead to an overexpression of different adhesins. While the 
adhesins were not regulated in a homogenous fashion for all the studied strains, we 
observed that EPA1 played a prominent role being often up regulated as the only 
adhesin. An included non-subtelomerically located adhesin did not show any change in 
expression levels in GOF mutant strains compared to the wild type strain. Our findings 
point towards a complex regulation of adhesin expression through CgPDR1, implicating 
subtelomeric-silencing mechanisms. These processes could lead to enhanced adherence 
to host cells and thereby contribute to the observed gain in virulence in CgPDR1 
mutants. 
Keywords: Candida glabrata, CgPDR1, EPA, Adhesin, qPCR 
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III. INTRODUCTION 
III.1. Candida species and candidiasis 
Candida is a genus of yeasts that includes around 154 species. Certain species are 
frequent colonizers of human skin and mucous membranes and thus members of the 
normal flora of the skin, mouth, vagina, and stool. Candida species are also 
opportunistic pathogens, capable of causing infections following disruption of the 
normal flora, a breach in the mucocutaneous barrier or a defect in host cellular 
immunity. The microscopic features of Candida species show species-related variations. 
All species produce blastoconidia individually or in small clusters. Blastoconidia may 
be round or elongated. C. glabrata, for example, grows as a small, elliptical, unicellular 
budding yeast at all times. Rarely, buds of C. glabrata can adhere to one another in 
rudimentary short chains. In marked contrast, other Candida species like C. albicans 
form elliptical budding cells that are typically larger than those of C. glabrata; C. 
albicans also forms elaborate and well developed multicellular filaments or 
pseudohyphae which may be long, branched, or curved under certain growth conditions 
(Figure 1) (2). For most Candida spp. the morphology is fundamentally the same 
whether observed in vitro or in vivo. 
Figure 1 
Morphology of C. 
albicans. The figure 
shows the different morph-
ological features of C. 
albicans. The inset in the 
hyphae panel shows the 
appearance of a hyphal 
colony that has been 
growing for 5 days on 
Spider medium. Scale 
bars in the main panels 
represent 5 μm, and in the 
inset on the hyphae panel 
represents 1 mm Re-
produced from reference 
(2). 
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The most frequently isolated Candida species in human infections is C. albicans, the 
most abundant and significant species. However, C. glabrata and other Candida species 
are also isolated as causative agents of Candida infections. More importantly, there has 
been a recent increase in infections due to non-albicans Candida species. Currently C. 
glabrata accounts for up to 26% of bloodstream infections (BSIs) caused by Candida 
species in North America (6). 
The Candida genus is currently the most common cause of opportunistic mycoses 
worldwide and the fourth most common cause of healthcare-associated bloodstream 
infections in the United States. In some hospitals it is even the most common cause (5). 
These infections tend to occur in the sickest patients. The clinical manifestations of 
Candida species infections range from local mucous membrane infections to 
widespread dissemination with multisystem organ failure and often a devastating 
outcome for the patient. Major established risk factors for Candida species infection 
include the following amongst others (7): 
• Broad-spectrum antibiotics and colonization by Candida species  
• Decreased host defense (post transplantation immunosuppression, AIDS, 
neutropenia, genetic immune deficiency conditions) 
• Surgery, particularly major abdominal surgery 
• A prolonged stay in the ICU 
• Central venous catheters 
The prevalence of different Candida species varies considerably amongst the different 
hospital services. C. glabrata strains are the most common Candida species isolated 
from solid organ transplant (38.4% of infections) and hematopoietic stem cell 
transplant recipients (32.7% of infections) (5), two groups of patients receiving 
frequent azole antifungal prophylaxis. On the other hand, C. glabrata infections are 
almost absent in neonatal intensive care units where use of antifungal prophylaxis is 
generally low (Figure 2).  
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III.2. Candida glabrata 
C. glabrata, a haploid, asexual member of the Ascomycetes once believed to be non-
pathogenic, is currently regarded as the second most prevalent yeast pathogen in 
humans (6). In the environment C. glabrata, like C. albicans, is exclusively found in 
association with mammals, reflecting the success of the commensal lifestyle of these 
yeasts. Both species cause a similar constellation of BSIs and mucosal infections and 
have a primarily clonal population structure (Table 1). But despite these similarities C. 
glabrata and C. albicans are phylogenetically quite distinct (Fig. 3), suggesting that C. 
glabrata’s ability to infect humans emerged independently from that of other Candida 
species. C. glabrata shares common ancestry with several Saccharomyces species and, 
in spite of its name, clearly belongs to a clade different from that of other Candida 
species (1). Results of this evolutionary relatedness are, amongst others, a largely 
conserved chromosomal structure between S. cerevisiae (or baker’s yeast) and C. 
glabrata, as most genes have orthologues in the other species, and a similar stress 
response (1). However, one question left unanswered is the difference in pathogenicity 
between C. glabrata and its non-pathogenic relative S. cerevisiae. Attributes like 
Figure 2 
Allocation of different Candida species amongst patients with candidemia in different hospital 
services. aIncludes C. utilis, C. fermentati, C. kefyr, C. rugosa, C. famata, C. fennica, C. lambica, and C. 
lipolytica. HSCT = hematopoietic stem cell transplantation; ICU = Intensive care units; SOT = solid 
organ transplant. Reproduced from reference (5). 
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biofilm formation, increased adherence to host cells and invasion into host tissue, stress 
resistance and a reduced susceptibility to antifungal drugs (Fig. 4) seem to play a crucial 
role in the acquisition of pathogenicity of C. glabrata. 
 
TABLE 1, Comparison of C. glabrata, C. albicans and S. cerevisiae 
 C. glabrata C. albicans S. cerevisiae 
Ploidy: Haploid Diploid Diploid 
Virulence: Opportunistic pathogen 
Opportunistic 
pathogen Non-pathogenic 
Major sites of 
infection: 
Oral, vaginal, 
disseminated 
Oral, vaginal, 
disseminated Non-infectious 
Mating genes: Present Present Present 
Sexual cycle: Unknown Known (cryptic) Known 
Clonal population 
structure: Yes Yes No 
Phenotypic switching: Present Present Absent 
True hyphae: Absent Present Absent 
Pseudohyphae: Present Present Present 
Biofilm formation: Present Present Present 
Major adhesins: Lectins (encoded by EPA genes) 
Lectins Hwp1 
adhesin Als adhesins 
(ECM substrates) 
Lectins (encoded by 
FLO genes) Sexual 
agglutinins 
Auxotrophy: Niacin, thiamine, pyridoxine None None 
Azole resistance: Innate resistance Susceptible Susceptible 
Mitochondrial 
function: Petite positive Petite negative Petite positive 
Table adapted from reference (4) 
 
 
Figure 3 
Phylogeny of Candida species and other 
hemiascomycetes. C. glabrata and S. 
cerevisiae are phylogenetically closely 
related and are both quite distinct from 
other pathogenic Candida species. The 
evolution of the S. cerevisiae genome 
included a whole-genome duplication; 
this duplication occurred prior to the 
divergence of S. cerevisiae and C. 
glabrata. Reproduced from reference (4). 
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III.3. Treatment of C. glabrata infections and azole resistance 
C. glabrata infections can be treated with several antifungal agents including 
amphotericin B, azoles and echinocandins. However C. glabrata has a relatively low 
drug susceptibility compared to other Candida species, particularly regarding azole 
drugs. Azole drugs are a class of antifungals that have been widely used for the 
treatment of candidiasis ever since the approval of fluconazole, the most prominent 
member of the azole family, by the United States Food and Drug Administration (FDA) 
in 1990. It is a first line treatment for many fungal infections including disseminated 
candidiasis in non-neutropenic patients or Cryptococcosis (8). Azole antifungals work 
primarily by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-alpha-
demethylase, encoded by the ERG11 gene. This enzyme is necessary for the conversion 
of lanosterol to ergosterol, a vital component of the cellular membrane of fungi (4).  
One of the reasons for the rise in C. glabrata infections in recent decades has been its 
high drug resistance, in particular towards different azole antifungals. It has been shown 
that this azole resistance is almost exclusively mediated by enhanced drug efflux which 
in turn is caused by overexpression of multidrug transporters of the ABC (ATP Binding 
Cassette) family, among which are at least CgCDR1, CgCDR2 and CgSNQ2 (9, 10).  
Figure 4 
Pathogenicity factors and dis-
semination mechanisms of C. 
glabrata. C. glabrata cells can 
persist in environmental 
surfaces for several months. As 
a commensal, C. glabrata is 
found as part of the flora on 
interior mucosal areas of 
mammalians such as the gut. In 
immunocompromised patients, 
cells are able to disseminate 
into tissues and cause organ 
failure. Patrolling phagocytes 
are responsible for the 
extinction of invading yeast 
pathogens. The right panel lists 
genes thought to be important 
for the pathogenicity of C. 
glabrata. Re-produced from 
reference (1). 
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III.4. C. glabrata CgPDR1 
A major regulator of these ABC drug efflux transporters in C. glabrata is CgPDR1, a 
zinc finger transcription factor, which combines functional attributes of transcription 
factors PDR1 and PDR3 from S. cerevisiae (11). Deletion of CgPDR1 results in an 
increased susceptibility of C. glabrata to azole antifungals via the loss of 
overexpression of the involved ABC efflux transporters. In clinical isolates resistant to 
azole drugs, CgPDR1 exhibits so-called gain of function (GOF) mutations, which are 
responsible for the overexpression of ABC drug efflux transporters (CgCDR1, CgCDR2 
and CgSNQ2). There is not only one specific mutation responsible for the azole 
resistance of the different clinical isolates, but a strikingly high diversity amongst the 
CgPDR1 GOF mutations with as many as 67 described up to now (12, 13). 
Another surprising feature of GOF mutations in CgPDR1 is their role in fungal-host 
interaction. It has been shown that GOF mutations in CgPDR1 are associated with 
enhanced virulence and fitness in murine models. Mice infected with C. glabrata strains 
containing these GOF mutations showed higher fungal organ burden and shorter 
survival time in a model of systemic infection, where neutropenic mice were challenged 
with tail vein injections of different C. glabrata strains (13). The enhanced virulence of 
azole resistant PDR1 mutants in this study was a rather unexpected finding since it is 
generally accepted that the development of drug resistance in microbes is usually 
associated with a decline in virulence or fitness (14).  
A possible mechanism behind the enhanced virulence of C. glabrata strains with 
CgPDR1 hyperactivity could be a globally increased adherence to different epithelial 
cell lines and a decreased competitive uptake by macrophages (Fig. 5). Adherence to 
host epithelial surfaces is a key step in the host-pathogen interaction and is required for 
the successful establishment of colonization and infection by yeasts. A previous 
publication from our lab showed that hyperactive CgPDR1 alleles cause an increased 
adherence of C. glabrata yeast to CHO-Lec2 cell monolayers in comparison to the 
wild-type allele in an isogenic strain background (15). This strongly suggests the 
involvement of adhesins in the enhanced virulence mediated by CgPDR1 GOF 
mutations.  
Master Thesis of Medicine  Beat Moeckli 
9 
 
III.5. Adherence to host cells and Epa-adhesins 
In fungi the cell wall has multiple roles, providing structural support to the cell but also 
forming the interface between the yeast and its environment. In pathogenic fungi, cell 
wall proteins (CWPs) mediate interactions with host cells, allow adherence and, in some 
cases, even invasion of the host. CWPs are therefore an important virulence factor in 
pathogenic fungi (16). While not the only one, an important family of cell wall 
anchored adhesins in C. glabrata are the Epa adhesins. This large sub-family of 
glycophosphatidylinositol (GPI) anchored CWPs is composed of 17 members in the 
reference C. glabrata strain CBS138. Earlier studies reported an even larger number of 
EPA genes, namely 23, in the BG2 strain, another widely studied C. glabrata strain (17, 
18). For instance, orthologues of EPA4 and EPA5, present in BG2, are lacking in the 
CBS138 strain. Furthermore, none of the orthologous EPA genes in the different strains 
present a perfect homology (17). The structure of Epa proteins is typical of adhesins: an 
effector domain is followed by a low complexity region that is often spiked with 
internal tandem repeats called “megasatellites”. A C-terminal GPI anchor signal is 
required for adhesin function at the cell surface and therefore the sequences for the 
majority of the Epa proteins contain hydrophobic sequences for attachment of GPI 
anchors at their C-termini. 
Figure 5 
CgPDR1-mediated interactions of C. glabrata with host cells. The figure illustrates the enhanced 
adherence of CgPDR1 to epithelial cells, favoring colonization, and the decreased adherence to 
phagocytes, resulting in a decreased uptake and phagocytosis. These two mechanisms are possibly 
implicated in the enhanced virulence of CgPDR1 GOF mutant strains. 
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Remarkably, 44 of the 67 putative adhesins in C. glabrata and 14 of the 17 EPA-genes 
in CBS138 are encoded in subtelomeric loci (19) (Figure 6A). In this location they are 
subjected to chromatin-based transcriptional silencing. Silencing is initiated by Rap1 a 
duplex telomere DNA binding factor, which functions by recruiting a complex of 
proteins encoded by the SIR2, SIR3 and SIR4 genes. In current models, Sir2 possesses 
the key catalytic activity of the Sir complex. Sir2 is a NAD+-dependent histone 
deacetylase, which deacetylates histones H3 and H4 of a targeted nucleosome. This in 
turn is thought to provide high affinity binding sites for Sir3 and Sir4, which serve a 
primary structural role in the repressed chromatin. The Sir complex has the ability to 
move from the telomere itself across sub-telomeric regions sequentially deacetylating 
adjacent nucleosomes by Sir2 (4, 20, 21) (Figure 6B). Transcriptional silencing in C. 
glabrata has been shown to regulate transcription at four sub-telomeric EPA loci that 
encompass the coding regions of EPA1–7. Silencing depends, at least in part, upon the 
proximity of the silenced gene to the telomere, and decreases as the silenced gene is at 
longer distances from the telomere. Yeast strains carrying mutations in the genes 
implicated in chromatin based silencing mechanisms, such as a sir3Δ strain, are hyper 
adherent to a variety of cultured epithelial cell lines, owing to derepression of three EPA 
genes in particular: EPA1, EPA6 and EPA7 (22).  
 
Figure 6 
Location of EPA1-7 and subtelomeric chromatin based silencing mechanisms. (A) EPA1–7 are 
located at subtelomeric loci in C. glabrata. The positions of seven EPA genes at their respective 
chromosome end loci are shown. Pink arrowheads illustrate telomere repeats. (B) Illustration of the 
chromatin-based silencing mechanism in budding yeast. Rap1 is the duplex telomere DNA binding factor, 
while Cdc13/Stn1/Ten1 binds to single-stranded telomere DNA. Rap1 recruits Sir3 and Sir4, which in 
turn recruits Sir2. Sir3 and Sir4 can also interact with histones directly. Sir2’s deacetylase activity 
maintains the hypoacetylated state of histones and thereby decreases expression of a given gene. Red stars 
represent histone acetylation groups; green cylinders, nucleosomes. Figure reproduced from reference (3). 
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The currently available data points toward a strong implication of Epa adhesins in 
adherence to host cells and also virulence of C. glabrata. It has been shown that epa1Δ 
mutant strains display reduction to background levels in adherence to CHO Lec2 
epithelial cells (23). A mutant strain, deficient of the three major adhesins known to 
date (epa(1,6,7)Δ), displayed a decreased capability to colonize the bladder in a murine 
model of urinary tract infection (21). Another study showed that a C. glabrata strain 
lacking the EPA1-3 cluster exhibits a decreased virulence and produces a lower fungal 
burden in kidneys in a murine model of disseminated infection (18). 
Interestingly, microarray data presented in a previous publication of our lab (24) shows 
that a cluster of known and putative adhesins, including EPA1 and EPA12, is regulated 
in the same manner by all the tested CgPDR1 GOF mutations. This is remarkable, 
because different CgPDR1 mutations show otherwise very different pictures of gene 
expression regulation, rarely controlling the same genes in the same way. This fact 
makes these adhesins a perfect candidate for identifying the processes through which 
CgPDR1 hyperactivity mediates enhanced virulence.  
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IV. AIM AND IMPORTANCE OF THIS STUDY 
GOF mutations on CgPDR1 not only lead to resistance to azole antifungals, but they 
also result in higher virulence and fitness of the affected strains (13). Results of a 
previous study suggest that one possible mechanism causing the higher virulence in 
CgPDR1 GOF mutant strains is mediated by increased adherence to epithelial cell 
layers, thereby favoring epithelial colonization of the host by C. glabrata (15). This 
hypothesis is further supported by microarray data showing that adhesins, a group of 
cell wall proteins responsible for adherence, are consistently regulated by different GOF 
mutations in CgPDR1(24). The aim of this study is to analyze the implication of a 
number of known adhesins, with a focus on Epa1, Epa7, Epa12 and Pwp4, in the 
increased adherence of several CgPDR1 GOF mutant strains, by means of quantitative 
PCR gene expression analysis. The results of this study will allow a better 
understanding of the mechanisms of CgPDR1-mediated differences in the interaction of 
C. glabrata with host cells and adherence processes of C. glabrata in general, possibly 
identifying targets for future antibiotic therapy. 
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V. MATERIALS AND METHODS 
V.1. Choice of the tested adhesins 
The choice of the tested adhesins has been taken by including a range of different 
criteria. At first the range of known adhesins has been narrowed down by including 
microarray data of a previous experiment of our lab, revealing the genes that are 
differentially regulated in PDR1 GOF mutants (24). This selection of genes has been 
further narrowed down by studying the available information on the different adhesins 
in the available literature (17, 22, 23), leading to the inclusion of EPA1, the most 
studied adhesin to date, and an additional EPA adhesin, EPA7. EPA6, another well-
studied EPA-family member has not been included because of problems with the primer 
design due to the high sequence homology between EPA6 and EPA7. EPA12 has been 
included because it showed a consistent, strong regulation in all of the studied GOF 
mutant strains. PWP4 has been included to compare the expression of the EPA adhesins, 
which are located subtelomerically, to an adhesin that belongs to a different family and 
is not located in a subtelomeric region. 
V.2. Oligonucleotide design 
A primer pair and a Taqman probe, which hybridizes to the region between the primer-
specific sequences, were designed for the target genes with Geneious R7 (version 
7.1.05) software (Biomatters Ltd), taking the CBS138 strain as the reference genome. 
RDN5.8 was used as the reference gene with previously published primers and probe 
(25). All primers and probes were synthesized by Eurogentec (Table 2). 
TABLE 2, Primers and fluorescent probes used in RT PCR 
Gene  Primer / Probe Sequence (5’ – 3’) and 5’/3’ modificationsa 
R
D
N
5.
8 RDN5.8F CTT-GGT-TCT-CGC-ATC-GAT-GA 
RDN5.8-R GGC-GCA-ATG-TGC-GTT-CA 
RDN5.8-Pr FAM-ACG-CAG-CGA-AAT-GCG-ATA-CGT-AAT-GTG-TAMRA 
E
PA
1 EPA1a 95 ACC-GCA-AGA-AAA-TCC-TCC-TCC 
EPA1b 95 TGG-TGC-TGA-TGA-TAT-TGA-TTT-GTT-G 
EPA1pr 95 FAM-TGG-CCT-CCA-TTC-ATA-CCC-CAC-TTC-CA-TAMRA 
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E
PA
7 EPA7a 96 TGA-TTT-ACG-GAA-GAA-TGG-TTC-G 
EPA7b 96 TTA-CCG-GTA-ACA-CCA-TCA-ACT 
EPA7pr 96 FAM-TGG-GAT-CTA-AAT-ATG-CGG-CAT-CCC-AAC-A-TAMRA 
E
PA
12
 EPA12a 96 AAG-GGT-TTG-TCA-ATG-GAA-CTG 
EPA12b 96 CAC-CCT-TGG-AAA-ATT-CGG-ATC 
EPA12pr 96 FAM-TCG-GAA-GAA-AGG-TTC-TCA-CCC-ATG-CT-TAMRA 
PW
P4
 PWP4a 96 GAG-TAG-ATC-TAG-AAC-TGC-GGG 
PWP4b 96 AGT-GAT-CAA-CTG-GGA-ACT-ACC 
PWP4pr 96 FAM-ACC-CAG-CCC-TGC-AGT-GAG-TAC-TCT-TAMRA 
a Abbreviations: FAM, 6-carboxyfluorescein; TAMRA, 6-carboxy-N,N,N’,N’-tetramethylrhodamine; 
 
V.1. Strains used 
The C. glabrata strains used in this study are listed in Table 3. All strains are stored in 
20% glycerol stocks at -80°C. 
TABLE 3, C. glabrata strains used in this study  
Strain Background Strain Genotype Reference 
DSY562 Azole-susceptible clinical strain isolated from oropharynx (9) 
CBS138 Clinical strain isolated from feces CBS 
BG2 Clinical strain isolated from vagina (23) 
SFY93 DSY562 pdr1Δ::FRT (13) 
SFY114 DSY562 pdr1Δ::PDR1- SAT1 (13) 
SFY115 DSY562 pdr1Δ::PDR1L280F-SAT1 (13) 
SFY101 DSY562 pdr1Δ::PDR1R376W-SAT1 (13) 
SFY103 DSY562 pdr1Δ::PDR1D1082G-SAT1 (13) 
SFY105 DSY562 pdr1Δ::PDR1T588A-SAT1 (13) 
SFY109 DSY562 pdr1Δ::PDR1E1083Q-SAT1 (13) 
SFY111 DSY562 pdr1Δ::PDR1Y584C-SAT1 (13) 
SFY116 DSY562 pdr1Δ::PDR1P822L-SAT1 (13) 
VSY184 CBS138 pdr1Δ::FRT * 
VSY215 CBS138 pdr1Δ::PDR1- SAT1 * 
VSY216 CBS138 pdr1Δ::PDR1
L280F-SAT1 * 
VSY250 CBS138 pdr1Δ::PDR1R376W-SAT1 * 
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VSY251 CBS138 pdr1Δ::PDR1T588A-SAT1 * 
VSY249 CBS138 pdr1Δ::PDR1E1083Q-SAT1 * 
VSY248 CBS138 pdr1Δ::PDR1P822L-SAT1 * 
VSY143 BG2 pdr1Δ::FRT * 
VSY144 BG2 pdr1Δ::PDR1- SAT1 * 
VSY145 BG2 pdr1Δ::PDR1L280F-SAT1 * 
VSY146 BG2 pdr1Δ::PDR1R376W-SAT1 * 
VSY147 BG2 pdr1Δ::PDR1T588A-SAT1 * 
VSY211 DSY738 pdr1Δ::PDR1- SAT1 * 
VSY212 DSY738 pdr1Δ::PDR1L280F-SAT1 * 
VSY213 DSY2235 pdr1Δ::PDR1- SAT1 * 
VSY214 DSY2235 pdr1Δ::PDR1L280F-SAT1 * 
* Unpublished (Vale-Silva et. al) 
 
V.3. RNA extraction and cDNA synthesis  
Overnight cultures were prepared from the desired C. glabrata strains in 3 mL liquid 
YEPD Medium. Sample preparation was performed from either two or three biological 
replicates. The overnight cultures were diluted in 5 mL of fresh liquid YEPD medium 
and grown at 30°C until mid-logarithmic phase. Subsequently, the culture tubes were 
centrifuged and the pellet was re-suspended in 300 µL RNA buffer (0.1 M Tris HCl pH 
7.5, 0.1 M LiCl, 10 mM EDTA, 0.5% SDS) and transferred to screw top tubes. A 
volume of acid-washed 0.5 mm glass-beads equivalent to 200 µL and 300 µL 25:24:1 
phenol chloroform isoamyl alcohol were added and the cells lysed using the MP-
FastPrep (M/S 0.5, time 15 sec.). Then, tubes were centrifuged 1 min. at 14000 rpm. 
Following the centrifugation, 250 µL of the supernatants were transferred to clean 
Eppendorf tubes and mixed with 250µL 25:24:1 phenol chloroform isoamyl alcohol. 
After another centrifugation of 1 min. at 14000 rpm, supernatants were transferred to 
clean Eppendorf tubes and precipitated with 600µL chilled 100% ethanol. Tubes were 
vortexed for 10 s, placed on dry ice for 10 min. and then centrifuged for 2 min. at 4°C. 
After pouring off the supernatant, pellets were washed with ice-cold 70% ethanol and 
air-dried. Finally, pellets were re-suspended in H2O and RNA concentrations were 
determined by spectrophotometry (NanoDrop 2000, Thermo Scientific).  
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To remove contaminating DNA, 10 µg of each RNA preparation was treated with 
DNase using a DNA-freeTM DNA removal kit (Ambion). For the Reverse Transcription 
reactions, Transcriptor High Fidelity cDNA Synthesis Kit (Roche) has been used on 1 
µg of DNA-free RNA of each sample and the manufacturer’s instructions were 
followed. RNA samples were stored at -80°C and cDNA samples were stored at -20°C. 
V.4. Quantitative real-time PCR (qRT-PCR) 
Quantitative expression of the CgEPA1, CgEPA7, CgEPA12, and CgPWP4 genes was 
performed with the StepOne Real-time PCR System (Life Technologies). RT-PCR was 
carried out in a 10-µl volume containing the following reagents: 5 µl of iTaq Supermix 
with Rox (BioRad), each primer pair and the Taqman probe at a final concentration of 
200 nM for the primers and 100 nM for the probes and 1% of the total cDNA sample 
produced as described above. Each reaction was run in triplicate and data was analyzed 
with the StepOneTM software. For relative quantification of the target genes, each set 
of primer pairs and the Taqman probe were used in combination with the primers and 
probe specific for the RDN5.8 gene in separate reactions.  
For data analysis and fold change calculations, the Comparative CT Method was used. 
For each experiment a standard curve for the reference gene and the studied gene were 
included and the amplification efficiency was determined for all genes. The CT values 
of the target genes were normalized to the endogenous reference (RDN5.8). Fold 
changes were obtained from the mean normalized expression of the samples relative to 
the mean normalized expression of a selected wild type (WT) control (Equation 1). A 
twofold increase in the level of expression of each gene was arbitrarily considered as 
significant. 
Equation 1 
Comparative CT Method (ΔΔCT method). CT,X is the threshold cycle of the gene of interest and CT,R 
is the threshold cycle of the endogenous reference gene (RDN5.8). Test refers to the test cDNA sample 
and Control refers to the control cDNA sample. 
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VI. RESULTS 
VI.1. Expression of adhesins in DSY562 background 
In these experiments the expression of EPA1, EPA7, EPA12 and PWP4 in different 
GOF mutant strains in the DSY562 strain background, associated with enhanced 
virulence and drug resistance, has been compared to a DSY562 WT strain. The aim of 
this experiment was to study the influence of the different GOF mutations on the 
expression of the above-mentioned adhesins. 
 
The expression of EPA1 (Fig. 7) shows a heterogeneous pattern among the different 
GOF mutant strains ranging from a two-fold down regulation in the SFY105 strain 
(T588A mutation) to a four-fold up regulation in the SFY115 (L280F mutation) strain. 
The latter strain is the only one showing an up regulation of EPA1 expression. 
Figure 7 
Relative expression of EPA1 in different CgPDR1 GOF mutant strains compared to the wild-type 
strain SFY114. 
R e la tiv e  e x p r e s s io n  o f E P A 1 in  c o m p a r is o n  to  w ild -ty p e  s tr a in  S F Y 1 1 4
(D S Y 5 6 2 p d r 1 : :C g P D R 1 )
F
o
ld
 c
h
a
n
g
e
(L
o
g
2
 s
c
a
le
)
W T
(S F Y 1 1 4 )
L 2 8 0 F
(S F Y 1 1 5 )
R 3 7 6 W
(S F Y 1 0 1 )
D 1 0 8 2 G
(S F Y 1 0 3 )
T 5 8 8 A
(S F Y 1 0 5 )
E 1 0 8 3 Q
(S F Y 1 0 9 )
Y 5 8 4 C
(S F Y 1 1 1 )
P 8 2 2 L
(S F Y 1 1 6 )
0 .2 5
0 .5
1
2
4
8
1 6
3 2
Master Thesis of Medicine  Beat Moeckli 
18 
EPA7 and EPA12 (Fig. 8) seem to have  an increased expression in the different GOF 
mutant strains, showing a 2 to 8 fold upregulation compared to the WT strain.  
Figure 8 
Relative expression of EPA7 and EPA12 in different CgPDR1 GOF mutant strains compared to the 
wild-type strain SFY114. 
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Figure 9 
Relative expression of PWP4 in different CgPDR1 GOF mutant strains compared to the wild-type 
strain SFY114. 
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The expression of PWP4 does not seem to be affected by the different CgPDR1 GOF 
mutations and lacks a significant difference in the level of expression in comparison to 
the WT strain (Fig. 9). 
VI.2. Expression of adhesins in CBS138 background 
In this experiment the expression of EPA1, EPA7, EPA12 and PWP4 was analyzed in 
strains carrying CgPDR1 alleles with the same GOF mutations as in the previous 
experiment but this time in the CBS138 strain background. The goal was to study the 
influence of the strain background on the expression levels of adhesins. A WT strain 
and a GOF mutant strain (L280F) on the DSY562 background have been included for 
comparison (data not shown).  
 
EPA1 shows at least a two-fold overexpression in all of the tested strains except for the 
P822L GOF mutant strain, in which EPA1 seems to be down regulated in comparison to 
the WT strain (Fig. 10). 
Figure 10 
Relative expression of EPA1 in different CgPDR1 GOF mutant strains compared to the wild-type 
strain VSY215. 
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The expression levels of EPA7, EPA12 and PWP4 in the different GOF mutant strains 
do not show a significant change in comparison to the wild-type expression of these 
adhesins. The only GOF mutant strain showing an overexpression is E1083Q, 
presenting an overexpression of EPA7 and EPA12. The PWP4 expression, again, stays 
unchanged in comparison to the wild type expression level (Fig. 11). 
VI.3. Expression of adhesins in BG2 and DSY2235 backgrounds 
The goal of this experiment was to study the expression of EPA1 and EPA7 in the 
available mutant strains in BG2 and DSY2235 backgrounds with an aim of analyzing 
the influence of the strain background on the expression levels of adhesins. Again, WT 
and GOF mutant strain L280F on the DSY562 background have been included for 
comparison (data not shown). 
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Figure 11 
Relative expression of EPA7, EPA12 and PWP4 in different CgPDR1 GOF mutant strains compared 
to the wild-type strain VSY115. 
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Figure 12 
Relative expression of EPA1 and EPA7 in different GOF mutant strains in a BG2 background 
relative to the BG2 wild type strain VSY144. 
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Figure 13 
Relative expression of EPA1 and 
EPA7 in the L280F mutant strain in 
DSY2235 background compared to 
the DSY2235 WT strain VSY213. 
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EPA1 appears to be overexpressed above the two fold threshold in all three of the 
studied GOF mutant strains (L280F, R376W and T588A) in the BG2 background, while 
the expression of EPA7 does not seem to be affected by either of the analyzed GOF 
mutant strains in the BG2 background (Fig. 12). Neither EPA1 nor EPA7 seem to be 
significantly overexpressed in the L280F GOF mutant in the DSY2235 background, 
although EPA1’s relative expression is very close to the two-fold threshold (Fig. 13).  
VI.4. Comparison of adhesin-expression in DSY562, CBS138 and 
BG2 backgrounds 
Since we have observed substantial differences in adhesin expression between the 
different strain backgrounds in the previous expression experiments, we decided to 
compare the expression of EPA1 in the different strain backgrounds expressing the wild 
type alleles of CgPDR1 (originally from DSY562) in a single experiment. 
 
Expression of EPA1 is highest in the CBS138 strain background, lowest in the DSY562 
background, and in between the two levels for the BG2 background. The difference is 
remarkable with over a 40-fold difference (Fig. 14) between the expression levels of 
EPA1 in the DSY562 and CBS138 wild type. 
  
Figure 14 
EPA1 expression in BG2, 
DSY562 and CBS138 wild type 
strains relative to the DSY562 
wild type strain SFY114. 
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VII. DISCUSSION, CONCLUSION AND OUTLOOK 
VII.1. Regulation of adhesin expression by CgPDR1 hyperactivity 
The tested isogenic strain collections with different CgPDR1 GOF mutations all 
presented an overexpression of at least one of the analyzed adhesins. This highly 
suggests that CgPDR1 hyperactivity has an important influence on the expression of 
adhesins in C. glabrata. Additionally, the results vary between different C. glabrata 
strains, revealing an important influence of the genetic background. 
In the DSY562 isogenic strain collection EPA1 is only overexpressed in the SFY115 
strain (L280F mutation) out of all the tested strains. EPA7 and EPA12, on the other 
hand, are overexpressed in all the studied strains. In the CBS138 isogenic strain 
collection EPA1 is the only overexpressed adhesin, while EPA7 and EPA12 do not seem 
to be affected by the CgPDR1 GOF mutations in this strain background. The same 
picture presents itself for the isogenic strain collection in the BG2 strain background. 
PWP4, in contrast to the other tested adhesins, is located in a non-subtelomeric location. 
Interestingly this fact correlates with the finding that CgPDR1 GOF mutations and 
strain backgrounds have absolutely no influence on the expression of PWP4. The 
expression levels of PWP4 through all the performed experiments have never exceeded 
the two-fold threshold level set as a limit for up or down regulation. This finding 
supports the idea that CgPDR1 mediated hyper-adherence involves subtelomeric 
regulation mechanisms.  
The differential regulation of adhesins between the tested strain backgrounds and the 
different GOF mutations, combined with the fact that the tested non-subtelomeric 
adhesin (PWP4) shows no regulation through CgPDR1, strongly points toward a 
complex indirect regulation of the adhesin expression through CgPDR1. This is further 
supported by the fact that subtelomeric regions are subjected to a complex regulation 
with a multitude of involved enzymes and regulation factors (16). However, direct 
regulation of at least some of the tested adhesins cannot be excluded at this point and 
additional work is required to confirm this theory. 
Master Thesis of Medicine  Beat Moeckli 
24 
VII.2. Correlation between adherence to epithelial cells and 
adhesin expression 
In experiments conducted simultaneously to my work at our lab, the adherence of 
different CgPDR1 GOF mutation strains to mammalian epithelial cells was measured. 
Concerning the DSY562 strain background, the SFY115 strain (L280F mutation) 
showed an approximately 30% increase in adhesion to epithelial cells compared to the 
WT, while other GOF alleles did not lead to increased adhesion (Vale-Silva et al., 
unpublished data). This shows a perfect correlation with the results of EPA1 expression. 
EPA1 is overexpressed in the strain bearing the L280F mutation only, while other 
CgPDR1 mutations do not seem to affect it. In light of these data, EPA1 was knocked 
out in strain SFY115 (L280F mutation in the DSY562 background) and this eliminated 
the differences in adhesion (Vale-Silva et al., unpublished data). These observations 
strongly suggest that EPA1 is solely responsible for the additional adhesion to epithelial 
cells mediated by the L280F GOF mutation on CgPDR1 in the DSY562 background. 
On the other hand, EPA1 does not seem to be implicated in the baseline adherence of 
these strains under the tested conditions. Other strains with different GOF mutations of 
the same isogenic strain collection (DSY562 background) lack significant differences in 
adherence to CHO-Lec2 cells and, as expected, did not show any regulation of the 
EPA1 expression. These two findings combined identify EPA1 as a possible key player 
of CgPDR1 mediated adherence in at least the DSY562 background. 
In the other tested strains and backgrounds (BG2 and CBS138) the situation seems to be 
more complex and the correlation between adherence to epithelial cells and EPA1 
expression is only partially given. Another observation made from the adherence 
experiments is that the different strains and backgrounds tested showed a high 
difference in absolute adhesion to epithelial cells ranging from 20-30% (BG2); ~50% 
(DSY562); ~70% (CBS138) and do not correlate entirely with EPA1 expression levels. 
Together these findings suggest that the increased adherence due to hyperactivity of the 
CgPDR1 GOF mutations observed in strains other than SFY115 (L280F mutation in the 
DSY562 background) is not only mediated by EPA1 but also by other adhesions. 
In BG2 the observed adherence was the lowest out of the three tested strain 
backgrounds, with just above 20% absolute adherence in the VSY145 strain (L280F 
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GOF mutation in BG2 background). Furthermore, the impact of an EPA1 knockout in 
this strain is the highest, with an adherence that almost goes back to background levels 
(23). The gene expression results showed an overexpression of EPA1 with no change of 
the EPA7 expression in the GOF mutant strains. These findings imply that EPA1 plays a 
predominant, if not exclusive role in the regulation of adherence in the C. glabrata BG2 
strain, further supported by previous publications (23). 
In conclusion we can say, that this present work was crucial to help identify EPA1 as a 
key player in the observed increased adherence mediated by CgPDR1 GOF mutations in 
our studied strains. 
VII.3. Difficulties and limitations of the current work 
The primers for the adhesin expression analysis were designed with help of the CBS138 
reference genome sequence. However, the expression analysis itself was performed on 
different strain backgrounds, including DSY562, BG2, DSY2235 and DSY738. We 
therefore took the risk of having mismatches in the sequences targeted by the primer in 
the different strains. We tried to minimize this risk by avoiding parts of the adhesin 
genes that showed a high heterogeneity between the two available genome sequences of 
the BG2 and CBS138 strains. Nevertheless the result of full genome sequencing of the 
DSY562 strain, obtained after the start of the experiments, showed several mismatches 
of the EPA7 gene sequence targeted by our primers (Table 3) between the CBS138 and 
the newly obtained DSY562 sequence. Therefore, it cannot be excluded that the 
amplification efficacy of EPA7 was suboptimal for the expression analysis in strain 
backgrounds other than CBS138. This is further supported by the low amplification 
efficacy calculated for the EPA7 RT-qPCR expression analysis in DSY562 background 
strains. We did not encounter the same problem for the expression analysis of EPA1, 
EPA12 and PWP4, where the targeted sequences were identical between the CBS138 
and the DSY562 genome and amplification efficacy was within normal limits. 
A weakness of the present work lies in the fact that C. glabrata was grown under 
laboratory conditions before RNA extraction, which only partially represents the 
physiological environment in which this pathogen is encountered. It is well known that 
environmental factors such as pH and growth phase of the yeast have a substantial 
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influence on the expression of adhesins in C. glabrata (19, 22). It would therefore be of 
high significance to study the impact of human epithelial cells co-cultured with the C. 
glabrata yeast on the expression of different adhesins. A murine model of infection 
would allow an even closer approximation of the infection mechanisms and adhesion 
patterns encountered in patients infected by C. glabrata. 
VII.4. Perspectives and outlook 
To obtain a clearer and more conclusive understanding of the regulation of adhesins 
through CgPDR1, it would be necessary to study the expression of further adhesins in 
different locations of the genome. This would additionally allow for a deeper 
understanding of the implication of subtelomeric mechanisms in the regulation of 
adherence mediated by CgPDR1. Likewise it would be of great help for the 
understanding of CgPDR1 hyperactivity-mediated adherence to analyze additional 
strains with CgPDR1 GOF mutations for their adherence properties to epithelial cells. 
In order to better understand the mechanisms of how CgPDR1 regulates the expression 
of adhesins it would be of high interest to investigate, as a first step, the interaction of 
Pdr1 with different promoter regions of EPA1. This would shed light on the direct 
interaction between Pdr1 and EPA1. As a next step Chromatin Immunoprecipitation 
(ChIP) could help to gain further insight in the pathways in which CgPdr1 interacts with 
its targets and eventually regulates the expression of adhesins. 
In order to further study the contribution of different adhesins in the enhanced virulence 
mediated by CgPDR1 hyperactivity, one could knock out different adhesins in a strain 
where enhanced virulence has been observed. A comparison of the virulence of this new 
strain with its parent strain would give us an idea of the contribution of adhesins in the 
gained virulence through CgPDR1 hyperactivity. 
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